Latest Content

Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.

This week, learn about the first death from a meat allergy caused by ticks, Gilead reports positive top-line data showing its investigational combination therapy, bictegravir/lenacapavir was efficacious and safe, a discussion around antibiotic alternatives for MRSA, and more.

Nathan Shively, MD, talks about the increase of this antibiotic at his institution over the last several years for a variety of infections, particularly osteomyelitis. He also provides insights about dalbavancin's profile including its efficacy and adverse effects.

The Leapfrog Group has released its Fall 2025 Hospital Safety Grades showing states such as Utah and New Jersey remain in the top 5 of rankings. Data on health systems is also included in the report.

A healthy New Jersey man succumbed to the allergy after eating red meat. A blood sample collected post-mortem found that he had been sensitized to the sugar, alpha-gal, found in mammals. The blood sample indicated the man had an extreme reaction, in line with what is seen in fatal anaphylaxis.

ByHeart Whole Nutrition Infant Formula is the product involved in the recall. Fifteen infants have been hospitalized in 12 states prompting a federal investigation. Clinicians are urged to treat on suspicion and report all cases.

Gilead reports its investigational single tablet of bictegravir and lenacapavir was efficacious in people with HIV who are virologically suppressed and who switched from taking multitablet regimens. The company says its phase 3 study results will form the basis for its future regulatory submissions.

During National C difficile Awareness Month, the Peggy Lillis Foundation is working toward greater awareness about prescribing practices as well as cleaning methods that can prevent infections.

The tool's developer, LIV Process, says it has created a water-based reagent that illuminates Clostridioides difficile on surfaces so teams can verify cleaning in real time.

Immunocore’s first-in-human study of its bispecific, IMC-I109V, demonstrated early antiviral activity and a favorable safety profile, supporting continued development of the TCR bispecific candidate as a potential functional cure for chronic hepatitis B.

In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.

Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN.1 subvariants.

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.